No Data
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $42
Stifel analyst Bradley Canino maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and adjusts the target price from $40 to $42.According to TipRanks data, the analyst has a success rate of
Express News | Syndax Pharmaceuticals Inc : Stifel Raises Target Price to $42 From $40
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Syndax Pharmaceuticals(SNDX.US) Officer Buys US$25,037.25 in Common Stock
$Syndax Pharmaceuticals(SNDX.US)$ Officer Goldan Keith A. purchased 1,250 shares of common stock on Jun 14, 2024 at an average price of $20.0298 for a total value of $25,037.25.Source: Announcement Wh